NMDA Receptor and Schizophrenia: A Brief History

Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: Evidence from genetically modified mouse models and pharmacological inhibition

(2011) Hanns Möhler et al.   BIOCHEMICAL PHARMACOLOGY

De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia

(2011) G Kirov et al.   MOLECULAR PSYCHIATRY

The NMDA receptor co-agonists, d-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex

(2011) Darrick T. Balu et al.   NEUROBIOLOGY OF DISEASE

Impaired NMDA receptor transmission alters striatal synapses and DISC1 protein in an age-dependent manner

(2011) A. J. Ramsey et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis

(2010) Guochuan Tsai et al.   CURRENT PHARMACEUTICAL DESIGN

The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects

(2009) M Liem-Moolenaar et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Prolonged Exposure to NMDAR Antagonist Suppresses Inhibitory Synaptic Transmission in Prefrontal Cortex

(2008) Yuchun Zhang et al.   JOURNAL OF NEUROPHYSIOLOGY

Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia

(2008) John E. Lisman et al.   TRENDS IN NEUROSCIENCES